IGC — IGC Pharma, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1326205 ·
Last close
$0.19
Market Cap
$19.43M
52W High
$0.36
52W Low
$0.08
ADV30
481,992
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 328,000 61,000 -1,931,000 -2,046,000 9,729,000 377,000 3,228,000
Jun 2026 — — — — — — —
Mar 2026 317,000 55,000 -2,458,000 -2,402,000 9,185,000 207,000 3,064,000
Dec 2025 350,000 44,000 -2,941,000 -726,000 9,712,000 900,000 2,289,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,943,000
Investing CF
$-192,000
Financing CF
$5,935,000
CapEx
$-823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.09
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-127,292,000
Inventory
$638,000
Receivables
$101,000
ST Investments
$28,000
EBIT TTM
$-10,203,000
Pretax Income TTM
$-6,548,000
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,106,000
EBITDA
$-7,524,000
Free Cash Flow
$-2,521,375
Enterprise Value
$21,404,802
Total Cash
$354,000
Total Debt
$1,082,000
Shares Out
103,384,008
Trailing EPS
$-0.07
Book Value
$0.06
ROE
-83.3%
ROA
-50.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2025 1,271,000 -7,446,000 -7,121,000 8,747,000 2,417,000 6,330,000 -4,065,000
Mar 2024 1,345,000 -9,798,000 -13,000,000 9,902,000 2,581,000 7,321,000 -5,199,000
Mar 2023 911,000 -11,571,000 -11,506,000 17,178,000 2,267,000 14,911,000 -7,047,000
Mar 2022 397,000 -15,428,000 -15,016,000 26,834,000 2,942,000 23,892,000 -7,462,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$9,496,000
Forward EPS
$-0.08

Peers — same industry

TickerNameMarket CapLastDaily %
COCP Cocrystal Pharma, Inc. $19.46M $1.01 —
ATOS ATOSSA THERAPEUTICS, INC. $18.96M $1.90 —
EDSA Edesa Biotech, Inc. $18.90M $1.96 —
CELU Celularity Inc $18.53M $0.57 —
CUE Cue Biopharma, Inc. $20.56M $2.83 —

News headlines (Yahoo Finance, 1h cache)

IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
2026-11-18 13:00 · Yahoo
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 13:00 · Yahoo
IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears
2026-11-05 15:18 · Yahoo
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
2026-10-13 12:00 · Yahoo
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
2026-09-28 12:00 · Yahoo
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
2026-08-11 12:30 · Yahoo
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
2026-07-29 12:30 · Yahoo
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
2026-07-09 13:00 · Yahoo
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
2026-04-22 12:30 · Yahoo
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
2026-06-02 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.